<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112099</article-id><article-id pub-id-type="publisher-id">ACM-40705</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_23994979.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  奥马珠单抗治疗过敏性哮喘的研究进展
  Research Progress of Omalizumab in the Treatment of Allergic Asthma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>晓伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>智远</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>才擎</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>山东省第二人民医院，山东 济南</addr-line></aff><aff id="aff3"><addr-line>威海市中医院，山东 威海</addr-line></aff><aff id="aff2"><addr-line>山东大学，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>682</fpage><lpage>689</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    奥马珠单抗(omalizumab)是一种人源化的抗人免疫球蛋白E单克隆抗体，通过阻止IgE与其受体相结合，抑制IgE介导的肥大细胞和嗜碱性粒细胞的活化和脱颗粒，进而有效减轻甚至避免其诱导的哮喘发作。本文综述了奥马珠单抗治疗过敏性哮喘的作用机制和临床应用现状，分析了其安全性与耐受性，并探讨了其应用前景。
    Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that effectively reduces or even prevents IgE from binding to its receptor, inhibiting IgE mediated activation and degranulation of mast cells and basophil cells, and thereby effectively alleviating or even avoiding asthma attacks induced by it. In this paper, the mechanism of action and clinical application of omalizumab in the treatment of allergic asthma were reviewed, its safety and tolerance were analyzed, and its application prospect was discussed. 
  
 
</p></abstract><kwd-group><kwd>过敏性哮喘，IgE，奥马珠单抗, Allergic Asthma</kwd><kwd> IgE</kwd><kwd> Omalizumab</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>奥马珠单抗(omalizumab)是一种人源化的抗人免疫球蛋白E单克隆抗体，通过阻止IgE与其受体相结合，抑制IgE介导的肥大细胞和嗜碱性粒细胞的活化和脱颗粒，进而有效减轻甚至避免其诱导的哮喘发作。本文综述了奥马珠单抗治疗过敏性哮喘的作用机制和临床应用现状，分析了其安全性与耐受性，并探讨了其应用前景。</p></sec><sec id="s2"><title>关键词</title><p>过敏性哮喘，IgE，奥马珠单抗</p></sec><sec id="s3"><title>Research Progress of Omalizumab in the Treatment of Allergic Asthma<sup> </sup></title><p>Xiaowei Ma<sup>1</sup>, Na Chen<sup>2</sup>, Zhiyuan Wang<sup>3</sup>, Caiqing Zhang<sup>3*</sup></p><p><sup>1</sup>Shandong University, Jinan Shandong</p><p><sup>2</sup>Weihai Hospital of Traditional Chinese Medicine, Weihai Shandong</p><p><sup>3</sup>The Second People’s Hospital of Shandong Province, Jinan Shandong</p><p><img src="//html.hanspub.org/file/38-1571942x4_hanspub.png" /></p><p>Received: Jan. 23<sup>rd</sup>, 2021; accepted: Feb. 7<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/38-1571942x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that effectively reduces or even prevents IgE from binding to its receptor, inhibiting IgE mediated activation and degranulation of mast cells and basophil cells, and thereby effectively alleviating or even avoiding asthma attacks induced by it. In this paper, the mechanism of action and clinical application of omalizumab in the treatment of allergic asthma were reviewed, its safety and tolerance were analyzed, and its application prospect was discussed.</p><p>Keywords:Allergic Asthma, IgE, Omalizumab</p><disp-formula id="hanspub.40705-formula55"><graphic xlink:href="//html.hanspub.org/file/38-1571942x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/38-1571942x8_hanspub.png" /> <img src="//html.hanspub.org/file/38-1571942x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>支气管哮喘(bronchial asthma)是一种异质性疾病，作为全球常见的慢性疾病之一，全世界哮喘患者约有3.34亿，预计到2025年，哮喘患者可升至4亿 [<xref ref-type="bibr" rid="hanspub.40705-ref1">1</xref>]。其中，过敏性哮喘约占70% [<xref ref-type="bibr" rid="hanspub.40705-ref2">2</xref>]，主要指由免疫球蛋白E (即IgE)所介导，并诱发变态反应的一种哮喘，临床诊断主要是存在明显的过敏反应以及对特定过敏原的IgE反应，可逆性气流受限和暴露于过敏原后引起的气道高反应性是其主要特点 [<xref ref-type="bibr" rid="hanspub.40705-ref3">3</xref>]。目前哮喘常规治疗药物主要有口服及吸入糖皮质激素、短效及长效β2肾上腺素受体激动剂及白三烯调节剂等。多数哮喘病人通过规律吸入ICS + LABA能够达到良好或完全的临床控制，仍有部分患者存在控制不佳、敏感性下降等问题，严重影响患者的生活质量。近些年来，随着精准医学的蓬勃发展，靶向治疗成为这一模式的重要组成部分。奥马珠单抗(omalizumab)作为首个抗IgE单克隆抗体，弥补了哮喘生物靶向治疗的空缺，成为中重度哮喘治疗的新选择。经过十余年的临床应用，展现了良好的应用前景。本文就奥马珠单抗(omalizumab)对过敏性哮喘的临床应用进展作一综述。</p></sec><sec id="s6"><title>2. 免疫球蛋白E</title><p>由于哮喘发病机制复杂，涉及多个领域，尚未完全阐明，随着研究的不断进展，IgE在哮喘发作中的作用，受到越来越多研究者的重视。IgE主要通过其在肥大细胞、嗜碱性细胞等细胞表面的两个受体(FcεRI和FcεRII)起作用 [<xref ref-type="bibr" rid="hanspub.40705-ref4">4</xref>]。通过对外周血特异性IgE的检测，结合患者病史，有助于病因诊断。</p><sec id="s6_1"><title>2.1. IgE的由来和结构</title><p>免疫球蛋白E的发现是变态反应和免疫学领域的一个重大突破。1921年，Prausnitz和Kustner发现了导致过敏反应的物质的第一条线索，四十年后，Ishizakas和他的同事将其鉴定为免疫球蛋白亚类。最终，1968年，世界卫生组织免疫球蛋白国际参考中心正式宣布出现第五种免疫球蛋白同种型，即IgE [<xref ref-type="bibr" rid="hanspub.40705-ref5">5</xref>]。自此它在过敏性疾病中的关键作用变得越来越清楚，填补了哮喘发病机制领域的空白。</p><p>IgE由两个重链和两个轻链组成，包含一个结构域(VH)的可变部分和四个结构域(Cε1、Cε2、Cε3、Cε4)的恒定片段 [<xref ref-type="bibr" rid="hanspub.40705-ref4">4</xref>]。在变态反应相关疾病中，IgE的致病作用主要通过Cε3与高亲和力(FcεRI)和低亲和力(FcεRII/CD23)受体结合。通过阻断IgE与其受体相结合，可以有效阻止炎症介质的释放，并从根源上抑制变态反应的发生 [<xref ref-type="bibr" rid="hanspub.40705-ref6">6</xref>]。另外，病毒性上呼吸道感染作为哮喘发作的诱发因素，可诱导高亲和力受体的表达和信号转导，并产生显著的IgE反应 [<xref ref-type="bibr" rid="hanspub.40705-ref7">7</xref>]。</p></sec><sec id="s6_2"><title>2.2. IgE的作用机制</title><p>外源性过敏原进入人体后，抗原递呈细胞通过其内吞作用使幼稚的T细胞对变应原敏感，并引导其发育为T辅助-2 (Th2)细胞。活化的Th2细胞可诱导IL-4和IL-13等炎性细胞因子的产生，并增加FcεRII的表达，进而激活B淋巴细胞，产生过敏原特异性IgE [<xref ref-type="bibr" rid="hanspub.40705-ref8">8</xref>]。过敏原多次进入人体后，可诱导肥大细胞和嗜碱性粒细胞与IgE交联，引发细胞脱颗粒，并释放组胺、类胰蛋白酶等血管活性介质，引起支气管平滑肌收缩、黏液高分泌及炎症细胞浸润，引发早期过敏反应，主要表现为水肿、血管扩张和支气管收缩 [<xref ref-type="bibr" rid="hanspub.40705-ref9">9</xref>]。速发型过敏反应发生后，在IL-3、IL-4等细胞因子和趋化因子的作用下，导致大量炎症细胞的聚集，由此引发迟发性过敏反应，临床上表现为粘液增多、气道高反应性和气道重塑等 [<xref ref-type="bibr" rid="hanspub.40705-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40705-ref10">10</xref>]。特异性记忆Th2细胞的激活和IgE促进的过敏原呈递也参与晚期过敏反应的发生 [<xref ref-type="bibr" rid="hanspub.40705-ref11">11</xref>]。</p></sec></sec><sec id="s7"><title>3. IgE抗体——奥马珠单抗</title><sec id="s7_1"><title>3.1. 制备与机制</title><p>人IgE免疫小鼠与骨髓瘤细胞融合形成的“杂交瘤”细胞，可以连续分泌抗免疫球蛋白E抗体，即奥马珠单抗(分子量150 kd) [<xref ref-type="bibr" rid="hanspub.40705-ref12">12</xref>]。利用杂交瘤技术研制的抗人IgE单克隆抗体 [<xref ref-type="bibr" rid="hanspub.40705-ref13">13</xref>]，奥马珠单抗仅含有5%甚至更少的小鼠残基，并且对非自身抗原决定簇产生免疫反应的风险非常低 [<xref ref-type="bibr" rid="hanspub.40705-ref14">14</xref>]。奥马珠单抗对IgE有着较高亲和力、IgE/omalizumab聚集物有着较强的稳定性，因而它们不会穿过血管壁，积聚在外周血以及上下呼吸道的粘膜中 [<xref ref-type="bibr" rid="hanspub.40705-ref15">15</xref>]。这就预示着奥马珠单抗在临床上的应用具有良好的安全性和耐受性。</p><p>阻止IgE与其受体相结合，进而有效减轻甚至避免其诱导的哮喘发作，成为哮喘治疗的突破点。奥马珠单抗以IgE为靶点，是治疗哮喘的第一种生物疗法 [<xref ref-type="bibr" rid="hanspub.40705-ref7">7</xref>]。通过与IgE的两个Cε3结构域选择性结合，形成IgE/抗IgE免疫复合物 [<xref ref-type="bibr" rid="hanspub.40705-ref16">16</xref>]，这些免疫复合物大小有限，并且易溶解，很难与补体结合、沉淀，因而体内的单核吞噬系统很容易将其吞噬、清除 [<xref ref-type="bibr" rid="hanspub.40705-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40705-ref17">17</xref>]。奥马珠单抗可以阻断IgE介导的炎症细胞的激活、炎症介质的释放，有效减少炎症细胞的聚集、组织重塑以及肺功能恶化。奥马珠单抗还可减少支气管网状基底膜厚度，从而延缓气道重塑 [<xref ref-type="bibr" rid="hanspub.40705-ref18">18</xref>]。因此，奥马利珠单抗能有效地减缓过敏性哮喘患者的免疫反应，从而显著改善哮喘症状的控制，并成功预防疾病恶化 [<xref ref-type="bibr" rid="hanspub.40705-ref4">4</xref>]。</p><p>由于IgE是过敏反应的关键介质，因此治疗IgE介导的过敏性疾病的一种方法是同时针对膜结合型和可溶性IgE。治疗型奥马利珠单抗与普通抗IgE的区别主要在于：普通抗免疫球蛋白E可以交叉连接FcεRI结合的IgE和聚合FcεRI。与普通抗IgE相比，奥马珠单抗不能与细胞表面已被FcεRI或CD23结合的IgE结合，也不能与血液中的可溶性CD23结合，但仍可结合于膜结合及可溶性IgE [<xref ref-type="bibr" rid="hanspub.40705-ref19">19</xref>]，不能模拟过敏原诱导的IgE交联。因此，奥马珠单抗是非过敏性的。</p></sec><sec id="s7_2"><title>3.2. 药效学和药代学</title><p>奥马珠单抗主要通过皮下注射给药，根据患者的体重及基线IgE水平，2至4周皮下给药一次，吸收的平均生物利用度约为62% [<xref ref-type="bibr" rid="hanspub.40705-ref20">20</xref>]。青少年及成人哮喘患者接受单次皮下注射后，吸收缓慢，平均给药后7~8天达到血清浓度的峰值。经多次给药后，奥马利珠单抗的血药浓度–时间曲线下面积明显增大，在稳定状态下，14天以上的曲线下面积是第一次给药后观察到的6倍 [<xref ref-type="bibr" rid="hanspub.40705-ref21">21</xref>]。omalizumab与IgE的Cε3结构域相互作用的竞争机制，决定了其有必要在7:1至15:1的范围内拮抗免疫球蛋白E的数量 [<xref ref-type="bibr" rid="hanspub.40705-ref22">22</xref>]。在给药剂量合理的情况下，经过单次皮下注射后，omalizumab可使血清游离IgE浓度降低84~99% [<xref ref-type="bibr" rid="hanspub.40705-ref23">23</xref>]。在哮喘患者中，奥马珠单抗的血清消除半衰期平均为26天，表观清除率平均为2.4 ml/kg/天 [<xref ref-type="bibr" rid="hanspub.40705-ref24">24</xref>]。目前，一般采用血清游离IgE浓度来评价奥马珠单抗的药效作用。</p></sec><sec id="s7_3"><title>3.3. 临床应用</title><p>奥马珠单抗在临床上的应用已有十余年，它的出现，为哮喘患者提供了新选择。根据我国哮喘控制的基本情况，奥马珠单抗目前主要适用于明确诊断为中重度过敏性哮喘的成年人(≥18周岁)或青少年(12~18周岁)患者 [<xref ref-type="bibr" rid="hanspub.40705-ref25">25</xref>]。</p><p>Vignola及其同事们发现，应用奥马珠单抗治疗28周后的中重度哮喘患者，其诱导哮喘生活质量问卷(AQLQ)得分显著改善 [<xref ref-type="bibr" rid="hanspub.40705-ref26">26</xref>]。选择合适的患者是成功抗IgE治疗过敏性哮喘的一个关键方面，通过治疗严重的、控制不充分的和口服类固醇依赖性哮喘患者可能获得最佳治疗效果。Humbert及其同事招募了419名患有严重过敏性哮喘的患者，在接受奥马珠单抗28周附加治疗后，疾病恶化程度显著降低，急救治疗和口服皮质类固醇的机会明显减少，与安慰剂治疗的患者相比，治疗组的患者在生活质量和呼气峰流量方面也有显著改善 [<xref ref-type="bibr" rid="hanspub.40705-ref27">27</xref>]。一项对来自186位患者的研究中，评估在常规治疗中加用奥马珠单抗后，在控制重度哮喘中的社会卫生支出，并分析其有效性，结果证明：在过敏性哮喘患者的治疗方案中添加奥马珠单抗是有效的，减少了直接和间接治疗费用，并显着改善了患者的健康状况 [<xref ref-type="bibr" rid="hanspub.40705-ref28">28</xref>]。在对3893名患者的研究中，经过52周奥马珠单抗的治疗，大多数患者的临床症状有所改善。所有患者中近一半在治疗后没有哮喘发作。证实了奥马珠单抗在大多数患者中的临床意义 [<xref ref-type="bibr" rid="hanspub.40705-ref29">29</xref>]。一项对现实生活中评估奥马珠单抗治疗哮喘长期疗效的研究中，通过对4年的观察研究，记录FEV1和ACT的改变，吸入ICS/LABA的剂量从65 (100%)经过4年的治疗(P &lt; 0.001)减少到25 (38.5%)；ACT成绩从15 &#177; 3在基线增加至23 &#177; 3 (P &lt; 0.001)和FEV1水平从55.6 &#177; 10.6至76.63 &#177; 10.34。证实了奥马珠单抗作为中度至重度哮喘的一个附加的治疗，导致更好哮喘控制，并且是有效且耐受性良好 [<xref ref-type="bibr" rid="hanspub.40705-ref30">30</xref>]。</p><p>Frix A N及其同事回顾性研究了2007年至2019年间应用omalizumab的157例严重过敏性哮喘患者，并评价其临床结局和气道炎症。在治疗4个月后，有76%的患者被判定受益于omalizumab，并且接受长期治疗。在随访过程中，哮喘得到了良好的控制，生活质量和肺活量测定功能均有改善，并且病情恶化率也持续下降。证明了奥马珠单抗通过降低病情恶化率，改善患者预后和气道口径以及减少2型气道炎症，在现实生活中对重度过敏性哮喘有效 [<xref ref-type="bibr" rid="hanspub.40705-ref31">31</xref>]。Pelaia Corrado等人通过对15例重度过敏性哮喘患者的一项单中心观察性研究，附加奥马珠单抗治疗后，哮喘控制评分、年度哮喘发作率显著降低，且具有统计学意义(P &lt; 0.0001)，显著增强FEV、减少血嗜酸性粒细胞数量(p &lt; 0.05)，进一步证实了奥马珠单抗改善重症2型哮喘的临床、肺功能和血液学特征的长期治疗能力 [<xref ref-type="bibr" rid="hanspub.40705-ref32">32</xref>]。Busse及其同事的一项涉及419名中度至重度哮喘的过敏性患者的随机对照研究，在奥马利珠单抗的60周附加治疗期间，季节性吸入皮质类固醇显著减少 [<xref ref-type="bibr" rid="hanspub.40705-ref33">33</xref>]。</p><p>支气管哮喘通常发病年龄较早，且人群中以中青年人居多。其中，青少年时期作为一个特殊的过渡时期，在哮喘的治疗中占有重要地位。Busse William W等人通过对340名12岁到17岁的青少年过敏性哮喘进行鉴定，治疗组中FEV1、百分比预测、用力肺活量的改善显著高于安慰组，且具有统计学意义(P &lt; 0.05)，强调了奥马珠单抗对青少年患者肺功能的改善作用，提示了在哮喘发展过程早期优化处理的重要性 [<xref ref-type="bibr" rid="hanspub.40705-ref34">34</xref>]。青少年患者的早期积极干预，在有效控制哮喘的同时，也能最大限度降低哮喘对患者的心理、健康负担，对青少年患者的学习、生活以及身体发育均有不可替代的作用。P G Gibson等人对来自澳大利亚21个诊所、接受奥马珠单抗治疗的180名严重过敏性哮喘患者进行了评估，其中，95%的患者有一种或多种合并症。根据ACQ-5中至少0.5的改善评估，奥马珠单抗有效率高达83%。口服糖皮质激素(OCS)的使用显著减少 [<xref ref-type="bibr" rid="hanspub.40705-ref35">35</xref>]。部分中重度持续性哮喘患者应用ICS + LABA难以控制时，需要仔细询问病史，并完善相关检查，明确是否存在合并症。变应性鼻炎、鼻窦炎、肥胖等因素，制约着哮喘症状的控制。对于存在合并症的哮喘患者，奥马珠单抗提供了新的治疗选择。</p></sec><sec id="s7_4"><title>3.4. 治疗时间</title><p>使用奥马珠单抗的关键是抗IgE治疗的持续时间。特别是，由于奥马珠单抗的治疗效果取决于其对IgE恒定部分的Cε3结构域的持续占有。奥马珠单抗的作用机制表明，为了阻断IgE功能并避免潜在的症状复发和病情恶化，因此可以认为该药物的给药应连续进行，不得中断，并根据终生计划使用 [<xref ref-type="bibr" rid="hanspub.40705-ref36">36</xref>]。目前认为，奥马珠单抗至少需连续使用12~16周，由于个体化差异，在治疗16周后，需要根据哮喘患者总体控制水平，决定可否继续应用奥马珠单抗治疗 [<xref ref-type="bibr" rid="hanspub.40705-ref25">25</xref>]。目前关于最佳治疗时间仍有一些争论，且尚无任何权威指南及倡议明确给出疗程的建议，但到目前为止，建议不要停止治疗，因为停止治疗会导致症状的复发。在持续应用奥马珠单抗治疗时，每3个月应当常规评估患者哮喘控制情况，控制良好，则可适当延长用药间隔甚至逐步停药，若症状加重，需重复使用 [<xref ref-type="bibr" rid="hanspub.40705-ref25">25</xref>]。</p><p>在终止奥马珠单抗的长期治疗后，血清中游离IgE浓度可升高，这与哮喘症状复发和病情加重有关。即便如此，Nopp和同事们进行了一项戒断试验，对18名应用奥马利珠单抗治疗6年的哮喘患者进行中断治疗，并观察其临床反应。经过3年的随访观察，其中，12人有着良好的哮喘控制和肺功能改善 [<xref ref-type="bibr" rid="hanspub.40705-ref37">37</xref>]。该报告与Baena Cagnani及其同事在一些阿根廷哮喘儿童中获得的后续发现一致，在抗IgE治疗中断后的最初3年随访期间，他们完全没有呼吸道症状。相比之下，Kuprys-Lipinska和Kuna的报告指出，11名波兰患者中，9名患者在停止奥马利珠单抗治疗后的前5个月内哮喘恶化复发 [<xref ref-type="bibr" rid="hanspub.40705-ref38">38</xref>]。此外，还伴随着ACT和AQLQ评分的恶化。无论如何，还需要进一步的研究来评估奥马珠单抗对哮喘病理生物学演变的潜在影响。</p></sec></sec><sec id="s8"><title>4. 安全性及耐受性</title><p>尽管奥马珠单抗是一种治疗哮喘生物疗法，但其仍具有潜在的副作用。在临床实践中，12岁及以上的青少年和成人哮喘患者最常见的不良反应为头痛和注射部位疼痛、肿胀等不良反应。奥马珠单抗存在I型局部或全身过敏反应的可能性，包括过敏反应和过敏性休克。这些过敏反应通常在应用奥马珠单抗后的2小时之内发生，部分可延迟至给药后24小时以上 [<xref ref-type="bibr" rid="hanspub.40705-ref39">39</xref>]。Di Bona Danilo及其同事回顾性评估了应用奥马珠单抗治疗9年的难治性哮喘患者，在对91名患者的长期随访中，仅有六名患者(6.6%)因与治疗相关的不良事件而中止了奥马珠单抗的治疗：关节痛/肌痛(3例)；荨麻疹、血管性水肿(1例)；子宫出血(1例)；复发性唇疱疹(1例)。omalizumab的长期治疗有着良好的安全性和耐受性。长时间使用奥马珠单抗治疗并没有增加副作用，特别是过敏反应的风险 [<xref ref-type="bibr" rid="hanspub.40705-ref40">40</xref>]。在Schreiber Jens的一项评估患者接受奥马珠单抗治疗哮喘相关控制的前瞻性研究中，通过对153名哮喘患者的为期3年观察，临床效果和安全性没有下降，支持了奥马珠单抗在哮喘控制和改善生活质量的重要作用 [<xref ref-type="bibr" rid="hanspub.40705-ref41">41</xref>]。奥马珠单抗的长期应用，对于心血管系统的影响有限，对包括3000多名参与者在内的8项对照试验的仔细分析表明，奥马利珠单抗相关的心血管风险与接受安慰剂治疗的患者的心血管风险相似 [<xref ref-type="bibr" rid="hanspub.40705-ref42">42</xref>]。然而，在Iribarren Carlos的一项前瞻性研究中，评估了奥马珠单抗和心血管事件之间潜在的关联。这项研究表明，与非奥马珠单抗组群相比，奥马珠单抗组群的CV/CBV事件发生率更高。组间哮喘严重程度的差异可能导致了这种不平衡，但也不能排除某些风险的增加 [<xref ref-type="bibr" rid="hanspub.40705-ref43">43</xref>]。值得注意的是，有研究指出，与安慰剂组相比，应用奥马珠单抗的哮喘患者恶性肿瘤发生率有所增加 [<xref ref-type="bibr" rid="hanspub.40705-ref23">23</xref>]。然而，最近一项前瞻性观察队列研究的结果表明，与普通人群相比，在接受奥马利珠单抗治疗的哮喘患者，恶性肿瘤发病率没有明显差异 [<xref ref-type="bibr" rid="hanspub.40705-ref44">44</xref>]。IgE作为一种免疫球蛋白，对寄生虫感染有着免疫监测和保护作用，应用奥马珠单抗治疗后，这种免疫保护作用存在被削弱的风险。有研究表明，在使用奥马珠单抗治疗的哮喘患者，其对蠕虫等寄生虫感染率略有增加 [<xref ref-type="bibr" rid="hanspub.40705-ref45">45</xref>]。因此，对于寄生虫感染流行地区或前往该地区的哮喘患者，在应用奥马珠单抗治疗之前，应当检测是否存在寄生虫感染，并进行治疗。此外，由于奥马珠单抗存在过敏反应的风险，并且可以通过胎盘屏障，对胎儿的影响尚未明确，因而不推荐孕妇使用 [<xref ref-type="bibr" rid="hanspub.40705-ref25">25</xref>]。</p></sec><sec id="s9"><title>5. 总结与展望</title><p>大多数哮喘患者表现为IgE介导的过敏性哮喘。最近几年的GINA报告重新定义了哮喘的概念，突出强调了其异质性和疾病表型的相关性，同时认识到特定的生物途径是治疗严重或难以控制的哮喘患者的新方法。奥马珠单抗显著的临床疗效和安全性受到越来越多临床医生的关注，是中重度过敏性哮喘治疗的显著进步。作为附加治疗，奥马珠单抗在预防哮喘急性发作、减少吸入或口服糖皮质激素的使用量、改善呼吸系统症状和提升患者生活质量方面具有显著疗效。对于奥马珠单抗在特定人群中的作用，如中度过敏、严重过敏和非过敏性哮喘患者，其疗效的评估尚需进一步的研究。由于高昂的价格及治疗的长期化，对患者使用的决心和依从性具有很大的挑战性。庆幸的是，伴随着奥马珠单抗走进了医保，相信会走进越来越多哮喘患者的生活。奥马利珠单抗在哮喘中地位的不断提升，临床应用前景会非常广阔。</p></sec><sec id="s10"><title>文章引用</title><p>马晓伟,陈 娜,王智远,张才擎. 奥马珠单抗治疗过敏性哮喘的研究进展Research Progress of Omalizumab in the Treatment of Allergic Asthma[J]. 临床医学进展, 2021, 11(02): 682-689. https://doi.org/10.12677/ACM.2021.112099</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40705-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">(2014) The Global Asthma Report 2014. Global Asthma Network, Auckland. 
http://www.globalasthmareport.org|resources|Global_Asthma_Report_2014</mixed-citation></ref><ref id="hanspub.40705-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">林江涛. 抗IgE治疗过敏性哮喘的长期有效性和安全性[J]. 中华结核和呼吸杂志, 2016, 39(9): 733-736.</mixed-citation></ref><ref id="hanspub.40705-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Schatz, M. and Rosenwasser, L. (2014) The Allergic Asthma Phenotype. The Journal of Allergy and Clinical Immunology: In Practice, 2, 645-649. ://doi.org/10.1016/j.jaip.2014.09.004</mixed-citation></ref><ref id="hanspub.40705-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pelaia, C., Calabrese, C., Terracciano, R., de Blasio, F., Vatrella, A. and Pelaia, G. (2018) Omalizumab, the First Available Antibody for Biological Treatment of Severe Asthma: More than a Decade of Real-Life Effectiveness. Therapeutic Advances in Respiratory Disease, 12, 1753466618810192. ://doi.org/10.1177/1753466618810192</mixed-citation></ref><ref id="hanspub.40705-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ribatti, D. (2016) The Discovery of Immunoglobulin E. Immunology Letters, 171, 1-4.  
://doi.org/10.1016/j.imlet.2016.01.001</mixed-citation></ref><ref id="hanspub.40705-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mitropoulou, A.N., Ceska, T., Heads, J.T., et al. (2020) Engineering the Fab Fragment of the Anti-IgE Omalizumab to Prevent Fab Crystallization and Permit IgE-Fc Complex Crystallization. Acta Crystallographica Section F: Structural Biology Communications, 76, 116-129. ://doi.org/10.1107/S2053230X20001466</mixed-citation></ref><ref id="hanspub.40705-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rath, N., Raje, N. and Rosenwasser, L. (2018) Immunoglobulin E as a Biomarker in Asthma. Immunology and Allergy Clinics of North America, 38, 587-597. ://doi.org/10.1016/j.iac.2018.06.007</mixed-citation></ref><ref id="hanspub.40705-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Navinés-Ferrer, A., Serrano-Candelas, E., Molina-Molina, G.J. and Martín, M. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Research, 2016, Article ID: 8163803.  
://doi.org/10.1155/2016/8163803</mixed-citation></ref><ref id="hanspub.40705-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Anto, J.M., Bousquet, J., Akdis, M., et al. (2017) Mechanisms of the Development of Allergy (MeDALL): Introducing Novel Concepts in Allergy Phenotypes. The Journal of Allergy and Clinical Immunology, 139, 388-399.  
://doi.org/10.1016/j.jaci.2016.12.940</mixed-citation></ref><ref id="hanspub.40705-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Galli, S.J. and Tsai, M. (2012) IgE and Mast Cells in Allergic Disease. Nature Medicine, 18, 693-704.  
://doi.org/10.1038/nm.2755</mixed-citation></ref><ref id="hanspub.40705-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Humbert, M., Bousquet, J., Bachert, C., et al. (2019) IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. The Journal of Allergy and Clinical Immunology: In Practice, 7, 1418-1429.  
://doi.org/10.1016/j.jaip.2019.02.030</mixed-citation></ref><ref id="hanspub.40705-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">(2002) Omalizumab: Anti-IgE Monoclonal Antibody E25, E25, Humanised Anti-IgE MAb, IGE 025, Monoclonal Antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs, 16, 380-386.  
://doi.org/10.2165/00063030-200216050-00009</mixed-citation></ref><ref id="hanspub.40705-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Presta, L.G., Lahr, S.J., Shields, R.L., et al. (1993) Humanization of an Antibody Directed against IgE. Journal of Immunology, 151, 2623-2632.</mixed-citation></ref><ref id="hanspub.40705-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Pelaia, G., Gallelli, L., Renda, T., et al. (2011) Update on Optimal Use of Omalizumab in Management of Asthma. Journal of Asthma and Allergy, 4, 49-59. ://doi.org/10.2147/JAA.S14520</mixed-citation></ref><ref id="hanspub.40705-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.W., Wu, P.C., Hsu, C.L. and Hung, A.F. (2007) Anti-IgE Antibodies for the Treatment of IgE-Mediated Allergic Diseases. Advances in Immunology, 93, 63-119. ://doi.org/10.1016/S0065-2776(06)93002-8</mixed-citation></ref><ref id="hanspub.40705-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hochhaus, G., Brookman, L., Fox, H., et al. (2003) Pharmacodynamics of Omalizumab: Implications for Optimised Dosing Strategies and Clinical Efficacy in the Treatment of Allergic Asthma. Current Medical Research and Opinion, 19, 491-498. ://doi.org/10.1185/030079903125002171</mixed-citation></ref><ref id="hanspub.40705-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fox, J.A., Hotaling, T.E., Struble, C., Ruppel, J., Bates, D.J. and Schoenhoff, M.B. (1996) Tissue Distribution and Complex Formation with IgE of an Anti-IgE Antibody after Intravenous Administration in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 279, 1000-1008.</mixed-citation></ref><ref id="hanspub.40705-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hoshino, M. and Ohtawa, J. (2012) Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma. Respiration, 83, 520-528. ://doi.org/10.1159/000334701</mixed-citation></ref><ref id="hanspub.40705-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Wright, J.D., Chu, H.M., Huang, C.H., Ma, C., Chang, T.W. and Lim, C. (2015) Structural and Physical Basis for Anti-IgE Therapy. Scientific Reports, 5, Article No. 11581. ://doi.org/10.1038/srep11581</mixed-citation></ref><ref id="hanspub.40705-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hendeles, L. and Sorkness, C.A. (2007) Anti-Immunoglobulin E Therapy with Omalizumab for Asthma. Annals of Pharmacotherapy, 41, 1397-1410. ://doi.org/10.1345/aph.1K005</mixed-citation></ref><ref id="hanspub.40705-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2016) Xolair-Product Information.  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf</mixed-citation></ref><ref id="hanspub.40705-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Marcus, P., Practice Management Committee, American College of Chest Physicians (2006) Incorporating Anti-IgE (Omalizumab) Therapy into Pulmonary Medicine Practice: Practice Management Implications. Chest, 129, 466-474.  
://doi.org/10.1378/chest.129.2.466</mixed-citation></ref><ref id="hanspub.40705-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Miller, C.W., Krishnaswamy, N., Johnston, C. and Krishnaswamy, G. (2008) Severe Asthma and the Omalizumab Option. Clinical and Molecular Allergy, 6, 4. ://doi.org/10.1186/1476-7961-6-4</mixed-citation></ref><ref id="hanspub.40705-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Luu, M., Bardou, M., Bonniaud, P. and Goirand, F. (2016) Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Omalizumab for the Treatment of Asthma. Expert Opinion on Drug Metabolism &amp; Toxicology, 12, 1503-1511.  
://doi.org/10.1080/17425255.2016.1248403</mixed-citation></ref><ref id="hanspub.40705-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">李靖. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3): 179-185.</mixed-citation></ref><ref id="hanspub.40705-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Vignola, A.M., Humbert, M., Bousquet, J., et al. (2004) Efficacy and Tolerability of Anti-Immunoglobulin E Therapy with Omalizumab in Patients with Concomitant Allergic Asthma and Persistent Allergic Rhinitis: SOLAR. Allergy, 59, 709-717. ://doi.org/10.1111/j.1398-9995.2004.00550.x</mixed-citation></ref><ref id="hanspub.40705-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of Omalizumab as Add-On Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled Despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy, 60, 309-316. ://doi.org/10.1111/j.1398-9995.2004.00772.x</mixed-citation></ref><ref id="hanspub.40705-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Martínez-Moragón, E., Climent, M., Chiner, E., Fernández-Aracil, C., Sánchez-Toril, F. and Lluch-Tortajada, I. (2019) Effectiveness and Pharmacoeconomic Analysis of the Treatment of Severe Asthma with Omalizumab in Clinical Practice. Efectividad y análisis farmacoeconómico del tratamiento del asma grave con omalizumab en la práctica clínica. Farmacia Hospitalaria, 43, 101-109.</mixed-citation></ref><ref id="hanspub.40705-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Adachi, M., Kozawa, M., Yoshisue, H., et al. (2018) Real-World Safety and Efficacy of Omalizumab in Patients with Severe Allergic Asthma: A Long-Term Post-Marketing Study in Japan. Respiratory Medicine, 141, 56-63.  
://doi.org/10.1016/j.rmed.2018.06.021</mixed-citation></ref><ref id="hanspub.40705-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Al-Ahmad, M., Arifhodzic, N., Nurkic, J., et al. (2018) “Real-Life” Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice, 27, 260-266. ://doi.org/10.1159/000487482</mixed-citation></ref><ref id="hanspub.40705-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Frix, A.N., Schleich, F., Paulus, V., Guissard, F., Henket, M. and Louis, R. (2020) Effectiveness of Omalizumab on Patient Reported Outcomes, Lung Function, and Inflammatory Markers in Severe Allergic Asthma. Biochemical Pharmacology, 179, Article ID: 113944. ://doi.org/10.1016/j.bcp.2020.113944</mixed-citation></ref><ref id="hanspub.40705-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Pelaia, C., Calabrese, C., Barbuto, S., et al. (2019) Omalizumab Lowers Asthma Exacerbations, Oral Corticosteroid Intake and Blood Eosinophils: Results of a 5-YEAR Single-Centre Observational Study. Pulmonary Pharmacology &amp; Therapeutics, 54, 25-30. ://doi.org/10.1016/j.pupt.2018.11.002</mixed-citation></ref><ref id="hanspub.40705-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Busse, W.W., Morgan, W.J., Gergen, P.J., et al. (2011) Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. The New England Journal of Medicine, 364, 1005-1015. ://doi.org/10.1056/NEJMoa1009705</mixed-citation></ref><ref id="hanspub.40705-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Busse, W.W., Humbert, M., Haselkorn, T., et al. (2020) Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents with Moderate-to-Severe Allergic Asthma. Annals of Allergy, Asthma &amp; Immunology, 124, 190-196. ://doi.org/10.1016/j.anai.2019.11.016</mixed-citation></ref><ref id="hanspub.40705-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Gibson, P.G., Reddel, H., McDonald, V.M., et al. (2016) Effectiveness and Response Predictors of Omalizumab in a Severe Allergic Asthma Population with a High Prevalence of Comorbidities: The Australian Xolair Registry. Internal Medicine Journal, 46, 1054-1062. ://doi.org/10.1111/imj.13166</mixed-citation></ref><ref id="hanspub.40705-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ledford, D., Busse, W., Trzaskoma, B., et al. (2017) A Randomized Multicenter Study Evaluating Xolair Persistence of Response after Long-Term Therapy. The Journal of Allergy and Clinical Immunology, 140, 162-169.e2.  
://doi.org/10.1016/j.jaci.2016.08.054</mixed-citation></ref><ref id="hanspub.40705-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Nopp, A., Johansson, S.G., Adédoyin, J., Ankerst, J., Palmqvist, M. and Oman, H. (2010) After 6 Years with Xolair; a 3-Year Withdrawal Follow-Up. Allergy, 65, 56-60. ://doi.org/10.1111/j.1398-9995.2009.02144.x</mixed-citation></ref><ref id="hanspub.40705-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kupryś-Lipińska, I. and Kuna, P. (2014) Loss of Asthma Control after Cessation of Omalizumab Treatment: Real Life Data. Postępy Dermatologii i Alergologii, 31, 1-5. ://doi.org/10.5114/pdia.2014.40553</mixed-citation></ref><ref id="hanspub.40705-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Cox, L., Platts-Mills, T.A., Finegold, I., et al. (2007) American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on Omalizumab-Associated Anaphylaxis. The Journal of Allergy and Clinical Immunology, 120, 1373-1377. ://doi.org/10.1016/j.jaci.2007.09.032</mixed-citation></ref><ref id="hanspub.40705-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Di Bona, D., Fiorino, I., Taurino, M., et al. (2017) Long-Term “Real-Life” Safety of Omalizumab in Patients with Severe Uncontrolled Asthma: A Nine-Year Study. Respiratory Medicine, 130, 55-60.  
://doi.org/10.1016/j.rmed.2017.07.013</mixed-citation></ref><ref id="hanspub.40705-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Schreiber, J., Schwab Sauerbeck, I. and Mailänder, C. (2020) The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study. Advances in Therapy, 37, 353-363. ://doi.org/10.1007/s12325-019-01135-w</mixed-citation></ref><ref id="hanspub.40705-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Rodrigo, G.J., Neffen, H. and Castro-Rodriguez, J.A. (2011) Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-On Therapy to Corticosteroids for Children and Adults with Asthma: A Systematic Review. Chest, 139, 28-35. ://doi.org/10.1378/chest.10-1194</mixed-citation></ref><ref id="hanspub.40705-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Iribarren, C., Rahmaoui, A., Long, A.A., et al. (2017) Cardiovascular and Cerebrovascular Events among Patients Receiving Omalizumab: Results from EXCELS, a Prospective Cohort Study in Moderate to Severe Asthma. The Journal of Allergy and Clinical Immunology, 139, 1489-1495.e5. ://doi.org/10.1016/j.jaci.2016.07.038</mixed-citation></ref><ref id="hanspub.40705-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Long, A., Rahmaoui, A., Rothman, K.J., et al. (2014) Incidence of Malignancy in Patients with Moderate-to-Severe Asthma Treated with or without Omalizumab. The Journal of Allergy and Clinical Immunology, 134, 560-567.e4.  
://doi.org/10.1016/j.jaci.2014.02.007</mixed-citation></ref><ref id="hanspub.40705-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Cruz, A.A., Lima, F., Sarinho, E., et al. (2007) Safety of Anti-Immunoglobulin E Therapy with Omalizumab in Allergic Patients at Risk of Geohelminth Infection. Clinical &amp; Experimental Allergy, 37, 197-207.  
://doi.org/10.1111/j.1365-2222.2007.02650.x</mixed-citation></ref></ref-list></back></article>